
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atsena Reports Positive Results in XLRS Gene Therapy Trial Part A of ATSN-201
Details : ATSN-201 is an investigational gene therapy that leverages one of the company’s novel spreading capsids, AAV.SPR, it is being developed for the treatment of X-linked retinoschisis (XLRS).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 19, 2025
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atsena Gets RMAT Designation for ATSN-201 Gene Therapy
Details : ATSN-201 is an investigational gene therapy that leverages one of the company’s novel spreading capsids, AAV.SPR, it is being developed for the treatment of X-linked retinoschisis (XLRS).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Bain Capital
Deal Size : $150.0 million
Deal Type : Series C Financing
Atsena Raises $150M Series C to Advance Ocular Gene Therapy
Details : The proceeds from the financing will be used to advance Atsena’s lead program, ATSN-201, for the treatment of X-linked retinoschisis (XLRS).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 02, 2025
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Bain Capital
Deal Size : $150.0 million
Deal Type : Series C Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atsena Gets FDA Fast Track for ATSN-201 Gene Therapy in X-Linked Retinoschisis
Details : ATSN-201 is an investigational gene therapy that leverages one of the company’s novel spreading capsids, AAV.SPR, it is being developed for the treatment of X-linked retinoschisis (XLRS).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 12, 2025
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atsena Initiates Phase I/II Gene Therapy Trial for X-linked Retinoschisis
Details : ATSN-201 is an investigational gene therapy that leverages one of the company’s novel spreading capsids, AAV.SPR, it is being developed for the treatment of X-linked retinoschisis (XLRS).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 08, 2025
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATSN-101
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Nippon Shinyaku
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Nippon and Atsena Partner for ATSN-101 in US and Japan
Details : Nippon Shinyaku will receive exclusive commercial rights of ATSN-101, a first-in-class, investigational gene therapy for the treatment of LCA1, in the U.S. and Japan.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
November 13, 2024
Lead Product(s) : ATSN-101
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Nippon Shinyaku
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atsena Receives ODD for ATSN-201 Gene Therapy in X-Linked Retinoschisis
Details : ATSN-201 utilizes AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of gene expression. It is being evaluated for the treatment of X-linked Retinoschisis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 17, 2024
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atsena Receives RPD Designation for ATSN-201 to Treat X-linked Retinoschisis
Details : ATSN-201 utilizes AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of gene expression. It is being evaluated for the treatment of X-linked Retinoschisis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
August 14, 2024
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atsena Announces Positive Data from Phase I/II trial of ATSN-201 Gene Therapy
Details : ATSN-201 utilizes AAV.SPR, a novel spreading capsid, to achieve therapeutic gene expression in central retina photoreceptors, being evaluated for X-linked Retinoschisis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atsena Therapeutics Starts Dosing in Phase I/II Trial of ATSN-201 Gene Therapy for XLRS
Details : ATSN-201 is an investigational gene therapy that leverages one of the company’s novel spreading capsids, AAV.SPR, it is being developed for the treatment of X-linked retinoschisis (XLRS).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 13, 2024
Lead Product(s) : ATSN-201
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
